Home Newsfeeds Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target.

March 8, 2023

1 minute read

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target.

What’s Going On With Software Company Sprinklr Shares Today?

December 7, 6:47 AM

Sprinklr Inc (NYSE: CXM) shares are diving by over 20% after the

May 7, 3:42 AM

The analyst sees the launch of a separate AI App Store, which would be the foundational launching pad for developers and consumers tapping into AI.

February 21, 12:08 PM

Canonic Ltd., a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) launched six second-generation hybrid cannabis products in Israel.

April 2, 11:00 AM

In the preceding three months, 10 analysts have released ratings for Carvana (NYSE:CVNA), presenting a wide array of…